Skip to main content
SpringerLink
Log in

Synopsis of Antibiotic Treatment

  • Chapter
  • First Online:
Book cover Helicobacter pylori

Abstract

Helicobacter pylori (H. pylori) is a common infection responsible for considerable morbidity and mortality worldwide. It is now recommended that all H. pylori infections be cured unless there are compelling reasons not to. Like other infectious diseases, the most reliable method to achieve high cure rates is to base therapy on the results of patient-specific susceptibility testing. Empiric therapy must be based on knowledge of the local susceptibility patterns tempered by data obtained from the patient concerning their antibiotic exposure. Data from clinical trials without susceptibility testing cannot be reliably used in other locations. Because of increasing resistance, triple therapies based on clarithromycin, metronidazole, or levofloxacin should only be used for susceptibility-based therapy. If there are no options other than to give empiric therapy, only those regimens proven to be effective locally should be used. Special efforts should be made to enhance patient adherence. In most regions 14-day four-drug combinations are required for successful empiric therapy. Testing to confirm cure should be routinely done.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Graham DY. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology. 2015;148:719–31. e3.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59:1143–53.

    Article  CAS  PubMed  Google Scholar 

  3. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014;12:177–86, e3; Discussion e12–3.

    Article  PubMed  Google Scholar 

  4. Li Y, Huang X, Yao L, Shi R, Zhang G. Advantages of moxifloxacin and levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta-analysis. Wien Klin Wochenschr. 2010;122:413–22.

    Article  CAS  PubMed  Google Scholar 

  5. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med. 2007;147:553–62.

    Article  PubMed  Google Scholar 

  6. Wu JY, Liou JM, Graham DY. Evidence-based recommendations for successful Helicobacter pylori treatment. Expert Rev Gastroenterol Hepatol. 2014;8:21–8.

    Article  CAS  PubMed  Google Scholar 

  7. Marcus EA, Inatomi N, Nagami GT, Sachs G, Scott DR. The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin. Aliment Pharmacol Ther. 2012;36:972–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Sachs G, Weeks DL, Wen Y, Marcus EA, Scott DR, Melchers K. Acid acclimation by Helicobacter pylori. Physiology. 2005;20:429–38.

    Article  CAS  PubMed  Google Scholar 

  9. Scott DR, Marcus EA, Wen Y, Oh J, Sachs G. Gene expression in vivo shows that Helicobacter pylori colonizes an acidic niche on the gastric surface. Proc Natl Acad Sci U S A. 2007;104:7235–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol. 2008;5:321–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology. 1998;115:1272–7.

    Article  CAS  PubMed  Google Scholar 

  12. Laxminarayan R, Bhutta Z, Duse A, Jenkins P, O’Brien T, Okeke IN, et al. Drug resistance. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al., editors. Disease control priorities in developing countries. 2nd ed. Washington, DC: World Bank; 2006. p. 1031–52.

    Google Scholar 

  13. Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, el-Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III consensus report. Gut. 2007;56:772–81.

    Article  CAS  PubMed  Google Scholar 

  14. Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection – the Maastricht IV/florence consensus report. Gut. 2012;61:646–64.

    Article  CAS  PubMed  Google Scholar 

  15. Kim SG, Jung HK, Lee HL, Jang JY, Lee H, Kim CG, et al. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. J Gastroenterol Hepatol. 2014;29:1371–86.

    Article  PubMed  Google Scholar 

  16. Bardhan K, Bayerdörffer E, Veldhuyzen van Zanten SJ, Lind T, Mégraud F, Delchier JC, et al. The HOMER study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection. Helicobacter. 2000;5:196–201.

    Article  CAS  PubMed  Google Scholar 

  17. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007;26:343–57.

    Article  CAS  PubMed  Google Scholar 

  18. Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol. 2011;8:79–88.

    Article  CAS  PubMed  Google Scholar 

  19. Graham DY, Lee SY. How to effectively use bismuth quadruple therapy: the good, the bad, and the ugly. Gastroenterol Clin N Am. 2015;44:537–63.

    Article  Google Scholar 

  20. Lu H, Zhang W, Graham DY. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol. 2013;25:1134–40.

    Article  CAS  PubMed  Google Scholar 

  21. Liang X, Xu X, Zheng Q, Zhang W, Sun Q, Liu W, et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol. 2013;11:802–7. e1.

    Article  CAS  PubMed  Google Scholar 

  22. Graham DY, Lu H. Furazolidone in Helicobacter pylori therapy: misunderstood and often unfairly maligned drug told in a story of French bread. Saudi J Gastroenterol. 2012;18:1–2.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009;14:109–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther. 2011;34:604–17.

    Article  CAS  PubMed  Google Scholar 

  25. Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2013;381:205–13.

    Article  PubMed  Google Scholar 

  26. Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (Hybrid) therapy for the final 7 days. Helicobacter. 2011;16:139–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection. Gastroenterol Clin N Am. 2010;39:465–80.

    Article  Google Scholar 

  28. Labenz J, Stolte M, Blum AL, Jorias I, Leverkus F, Sollböhmer M, et al. Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut. 1995;37:39–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Labenz J, Leverkus F, Börsch G. Omeprazole plus amoxicillin for cure of Helicobacter pylori infection. Factors influencing the treatment success. Scand J Gastroenterol. 1994;29:1070–5.

    Article  CAS  PubMed  Google Scholar 

  30. Yang JC, Lin CJ, Wang HL, Chen JD, Kao JY, Shun CT, et al. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol. 2015;13:895–905. e5.

    Article  CAS  PubMed  Google Scholar 

  31. World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003.

    Google Scholar 

  32. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97.

    Article  CAS  PubMed  Google Scholar 

  33. Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. Ann Intern Med. 1984;100:258–68.

    Article  CAS  PubMed  Google Scholar 

  34. O’Connor JP, Taneike I, O’Morain C. Improving compliance with Helicobacter pylori eradication therapy: when and how? Ther Adv Gastroenterol. 2009;2:273–9.

    Article  Google Scholar 

  35. de Boer WA. How to achieve a near 100 % cure rate for H. pylori infection in peptic ulcer patients. A personal viewpoint. J Clin Gastroenterol. 1996;22:313–6.

    Article  PubMed  Google Scholar 

  36. Graham DY, Lew GM, Malaty HM, Evans DG, Evans Jr DJ, Klein PD, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology. 1992;102:493–6.

    Article  CAS  PubMed  Google Scholar 

  37. Lee M, Kemp JA, Canning A, Egan C, Tataronis G, Farraye FA. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch Intern Med. 1999;159:2312–6.

    CAS  PubMed  Google Scholar 

  38. Al-Eidan FA, McElnay JC, Scott MG, McConnell JB. Management of Helicobacter pylori eradication – the influence of structured counselling and follow-up. Br J Clin Pharmacol. 2002;53:163–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Michael E. DeBakey VA Medical Center, 2002 Holcombe Blvd, Houston, TX, 77030, USA

    David Y. Graham MD

  2. HPGC Group, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran Tehran, Tehran, Iran

    Marjan Mohammadi

Authors
  1. David Y. Graham MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marjan Mohammadi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Y. Graham MD .

Editor information

Editors and Affiliations

  1. Seoul National University, Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea (Republic of)

    Nayoung Kim

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media Singapore

About this chapter

Cite this chapter

Graham, D.Y., Mohammadi, M. (2016). Synopsis of Antibiotic Treatment. In: Kim, N. (eds) Helicobacter pylori. Springer, Singapore. https://doi.org/10.1007/978-981-287-706-2_40

Download citation

  • DOI: https://doi.org/10.1007/978-981-287-706-2_40

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-287-705-5

  • Online ISBN: 978-981-287-706-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation